Generic Name and Formulations:
Hydrocortisone 5mg, 10mg, 20mg; tabs.
Indications for CORTEF:
See full labeling. Oral: initially 20–240mg daily. Parenteral: initially 100–500mg.
See full labeling. Oral: in single or divided doses. Replacement: 0.56mg/kg/day. Other indications: 2–8mg/kg/day. Parenteral: initially 0.56–8mg/kg/day in 3 or 4 divided doses.
Systemic mycoses. Live vaccination. Solu-Cortef: also premature infants (benzyl alcohol content), intrathecal administration, idiopathic thrombocytopenic purpura (IM preparations).
Not for epidural use; serious neurologic events may occur. Concomitant systemic fungal infections, active ocular herpes simplex, cerebral malaria: not recommended. Latent or active amebiasis. Strongyloides infection. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Renal insufficiency. Recent MI. CHF. Hypertension. Thyroid disorder. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Cirrhosis. Postmenopausal women (osteoporosis risk). Diabetes. Supplement with additional steroids in physiologic stress. Emotional instability. Psychotic tendencies. Myasthenia gravis. Avoid abrupt cessation. Alternate, intermittent or single-daily doses at 8AM minimize adrenal suppression. Monitor thyroid, weight, growth, fluid, electrolyte balance and intraocular pressure (w. therapy >6weeks). Pregnancy (Cat.C). Nursing mothers.
Potentiated by ketoconazole, macrolides, cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Caution with aspirin in hypoprothrombinemia. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. May suppress reactions to skin tests.
HPA axis suppression, masks infection, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance, Kaposi's sarcoma, pheochromocytoma crisis.
Tabs 5mg—50; 10mg, 20mg—100; Solu-Cortef 100mg (2mL)—1, 25; 250mg (2mL)—1, 25; 500mg (4mL), 1g (8mL)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Lithium Monotherapy Effective in Treating Bipolar Disorder in Children
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Computerized Training Programs for Schizophrenia Improve Cognitive Functioning
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Cost-Effective Telehealth Alternatives for Veterans With Depression
- Polygenic Risk Scores Could Aid in Identifying Bipolar Disorder, Schizophrenia
- Brief Impression Questionnaire Useful in Schizophrenia Diagnoses